Clinical researchers are getting trials to patients with COVID-19 faster than ever. Here are the latest Jefferson trials testing potential COVID-19 therapies.
Preliminary observations suggest a high incidence of COVID-19 in stroke patients, including younger patients who were otherwise healthy.
A new study finds that restoring the protein SV2 in a genetic form of ALS can correct abnormalities in transmission and even prevent cells from dying, providing a new target for future therapies.
The discovery further challenges the accepted scientific dogma that the lens is shut out from the immune protection.
An interdisciplinary research team establishes a new technological pipeline to build a 3D map of the neurons in the heart, revealing foundational insight into their role in heart attacks and other cardiac conditions
The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response, and is approved for the whole population including children and pregnant women.
From harnessing the power of the immune system to understanding the role of gut microbiota in combating COVID-19, Jefferson scientists are doing their part to find a way out of the pandemic
New clinical trial opened at Jefferson for novel COVID-19 treatment in ten days.
Social isolation can change our brain and our lives. What are signs loneliness is affecting us, and how do we combat it?
A new study on adversity during childhood explores whether perceptions of traumatic events can affect adult health as much as the events themselves
For news not listed on this page view the Jefferson News Archive.